Navigator Medicines Completes Last Participant Last Visit (LPLV) in Phase 1b Trial of NAV-240, an OX40L and Anti-TNFα Bispecific Antibody for Autoimmune DiseasesSCOTCH PLAINS, NJ., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage biotech company pioneering the advancement of best-in-class bispecific antibodies (bsAb) for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced successful completion of participant visits in the Phase 1b multiple-ascending dose study (MAD) of NAV-240.
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune DiseasesSCOTCH PLAINS, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage biotech company pioneering the advancement of best-in-class bispecific antibodies for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced further data from a Phase 1a double-blind, placebo-controlled, single ascending dose (SAD) study of its lead therapeutic candidate, NAV-240.
